BRAF, MEK and KIT inhibitors for melanoma: Adverse events and their management

Chinese Clinical Oncology

Volumn 3, Issue 3, 2014, Pages

  Livingstone, Elisabeth ^a   Zimmer, Lisa ^a   Vaubel, Julia ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adverse event (AE); BRAF inhibitor; KIT inhibitor; MEK inhibitor; Melanoma

Indexed keywords

EID: 84942987653     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2014.03.03     Document Type: Review

References (88)

1. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
2. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32.
5. Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J 2014;20:18-24.
6. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
7. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
8. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
9. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
10. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
11. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.
12. Carvajal RD, Hamid O, Antonescu CR. Selecting patients for KIT inhibition in melanoma. Methods Mol Biol 2014;1102:137-62.
13. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009;8:2079-85.
14. Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009;27:e20017.
15. Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib Therapy for Melanoma Patients with KIT Mutations. Clinical Cancer Research 2012;18:1457-63.
16. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011;117:2202-8.
17. Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012;30:2008-14.
18. Agency EM. Summary of product characteristics: Tafinlar 2013 [cited 14.02.2014]. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002604/WC500149671.pdf
19. Agency EM. Summary of product characteristics: Zelboraf 2013 [14.02.2014]. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf
20. Zimmer L, Livingstone E, Hillen U, et al. Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management. Arch Dermatol 2012;148:357-61.
21. Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013;31:e283-7.
22. Regnier-Rosencher E, Lazareth H, Gressier L, et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol 2013;169:934-8.
23. Iddawela M, Crook S, George L, et al. Safety and efficacy of vemurafenib in end stage renal failure. BMC Cancer 2013;13:581.
24. Wolf SE, Meenken C, Moll AC, et al. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer 2013;13:561.
25. Sandhu SS, Ling C, Lim L, et al. Vemurafenib (B-RAF inhibitor) associated uveitis in patients with metastatic cutaneous melanoma. Clin Exp Ophth 2012;40:118.
26. Joshi L, Karydis A, Gemenetzi M, et al. Uveitis as a Result of MAP Kinase Pathway Inhibition. Case Rep Ophthalmol 2013;4:279-82.
27. Klein O, Ribas A, Chmielowski B, et al. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013;31:e215-7.
28. Wisler JA, Afshari C, Fielden M, et al. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat. Toxicol Pathol 2011;39:809-22.
29. Muluneh B, Buie LW, Collichio F. Vemurafenib-associated pancreatitis: case report. Pharmacotherapy 2013;33:e43-4.
30. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
31. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chemistry & biology 1999;6:559-68.
32. Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367:2316-21.
33. Cebon JS, Flaherty K, Weber JS, et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). J Clin Oncol 2013;3:abstr 9016.
34. Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013;18:314-22.
35. Zimmer L, Vaubel J, Livingstone E, et al. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012;10:475-86.
36. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012;67:1265-72.
37. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-8.
38. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
39. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-21.
40. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-60.
41. Holderfield M, Lorenzana E, Weisburd B, et al. Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Res 2014;74:2238-45.
42. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
43. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366:480-1.
44. Monfort JB, Pages C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012;22:399-401.
45. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012;167:987-94.
46. Maldonado-Seral C, Berros-Fombella JP, Vivanco-Allende B, et al. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity. Dermatol Online J 2013;19:16.
47. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.
48. Degen A, Volker B, Kapp A, et al. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. Eur J Dermatol 2013;23:118.
49. Rinderknecht JD, Goldinger SM, Rozati S, et al. RASopathic skin eruptions during vemurafenib therapy. PLoS One 2013;8:e58721.
50. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-83.
51. Schmitt L, Schumann T, Inhoff O, et al. Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient. Case Rep Dermatol 2013;5:69-72.
52. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine 2011;365:1448-9; author reply 50.
53. Debarbieux S, Dalle S, Depaepe L, et al. Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy. Br J Dermatol 2013;168:1230-5.
54. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 2012;148:1183-5.
55. Zimmer L, Haydu LE, Menzies AM, et al. Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. J Clin Oncol 2014;32:816-23.
56. Sinha R, Lecamwasam K, Purshouse K, et al. Toxic Epidermal Necrolysis in a patient receiving Vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol 2014;170:997-9.
57. Wenk KS, Pichard DC, Nasabzadeh T, et al. Vemurafenib-induced DRESS. JAMA Dermatol 2013;149:1242-3.
58. Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, et al. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol 2014;41:326-8.
59. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosensitization. JAMA dermatology 2013;149:855-7.
60. Ducassou A, David I, Delannes M, et al. Radiosensitization induced by vemurafenib. Cancer Radiother 2013;17:304-7.
61. Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 2013;23:879-81.
62. Satzger I, Degen A, Asper H, et al. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013;31:e220-2.
63. Rompoti N, Schilling B, Livingstone E, et al. Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity. J Clin Oncol 2013;31:3844-5.
64. Harding JJ, Barker CA, Carvajal RD, et al. Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy. J Clin Oncol 2014;32:e54-6.
65. Taylor SR, Isa H, Joshi L, et al. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010;224 Suppl 1:46-53.
66. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56.
67. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9.
68. Catalanotti F, Solit DB, Pulitzer MP, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 2013;19:2257-64.
69. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
70. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:782-9.
71. Drugs.com. Mekinist Information from Drugs.com 2013-2014 [cited 14.02.2014]. Available online: http://www.drugs.com/sfx/mekinist-side-effects.html
72. Moreno Garcia V, Thavasu P, Blanco Codesido M, et al. Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br J Cancer 2012;107:1797-800.
73. Chen X, Schwartz GK, DeAngelis LM, et al. Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology 2012;79:1929-31.
74. Boasberg PD, Redfern CH, Daniels GA, et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 2011;68:547-52.
75. Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011;29:1114-21.
76. Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058-64.
77. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
78. Green JS, Norris DA, Wisell J. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases. Br J Dermatol 2013;169:172-6.
79. Drugs.com. Gleevec Information from Drugs.com 2013 [20.02.2014]. Available online: http://www.drugs.com/pro/gleevec.html
80. Drugs.com. Sprycel Information from Drugs.com 2013 [20.02.2014]. Available online: http://www.drugs.com/pro/sprycel.html
81. Drugs.com. Tasigna Information from Drugs.com 2013 [20.02.2014]. Available online: http://www.drugs.com/pro/tasigna.html
82. Drugs.com. Sutent Information from Drugs.com 2013 [20.02.2014]. Available online: http://www.drugs.com/pro/sutent.html
83. Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013;27:1471-80.
84. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.
85. Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.
86. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002;347:446.
87. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.
88. Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19:371-5.